THBS2 and prostate carcinoma: Based on bioinformatics analysis and survival data of prostate cancer patients from TCGA and GEO cohorts, a prognostic model was constructed using 9 genes (MYLK, FBLN1, PTGDS, TGFB1, MXRA8, PTN, COL1A1, THBS2, and MT1E), which was validated by clinical prognosis and correlation with tumor immunity.